ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.

A woman with stage 4 pancreatic cancer shares how a once-daily RAS inhibitor changed her energy, routine and time with family.

Immunotherapy is a mainstay of lung cancer treatment, and its side effects are different from chemotherapy's. Here are five to know, what they feel like and how care teams treat them.

Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.

Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.

A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.

Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.

For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.